• Home
  • NEW DAY MEDICINE
  • 2(40)2022
  • 101 -2 (40) 2022 — Chukhliaev P.V., Janibekov J.J. — EFFICACY AND SAFETY OF ANTIVIRAL THERAPY IN PATIENTS HOSPITALIZED WITH COVID-19

101 -2 (40) 2022 — Chukhliaev P.V., Janibekov J.J. — EFFICACY AND SAFETY OF ANTIVIRAL THERAPY IN PATIENTS HOSPITALIZED WITH COVID-19

EFFICACY AND SAFETY OF ANTIVIRAL THERAPY IN PATIENTS HOSPITALIZED WITH COVID-19

Chukhliaev P.V., Gabrichevsky Research Institute for Epidemiology and Microbiology Russian Federal Supervision Service for Consumer Rights Protection and People’s Welfare, Moscow, Russia

Janibekov J.J., Republican Children’s Infectious Diseases Hospital of the Republic of Karakalpakstan, Nukus, Uzbekistan

Khavkina D.A., Gabrichevsky Research Institute for Epidemiology and Microbiology Russian Federal Supervision Service for Consumer Rights Protection and People’s Welfare, Moscow, Russia

 Akhmedova M.D., Tashkent Medical Academy, Tashkent, Uzbekistan

 Ruzhentsova T.A. Gabrichevsky Research Institute for Epidemiology and Microbiology Russian Federal Supervision Service for Consumer Rights Protection and People’s Welfare, Moscow, Russia

Resume

The article presents the data of a post-registration observational study to evaluate the results of the use of remdesivir and favipiravir in an infectious hospital.

The aim is to evaluate the efficacy and safety of the use of the drugs remdesivir and favipiravir in hospitalized patients with pneumonia caused by the SARS-CoV-2 virus.

Materials and methods. The study included 150 patients aged 18 to 98 years hospitalized with COVID-19, confirmed by PCR and complicated by pneumonia. 60 patients received remdesivir, and 90 – favipiravir of these.

Results. The average period before reaching a satisfactory condition and discharge from the hospital was significantly less in the group receiving remdesivir than when using favipiravir. There is less need to replace therapy, there have been no cases of its cancellation due to poor tolerability when using remdesivir.

Conclusion. Remdesivir is a more effective and safer drug for the treatment of COVID-19 in patients with pneumonia.

Keywords: coronavirus infection, COVID-19, favipiravir, remdesivir, SARS-CoV-2, viral pneumonia.

First page

512

Last page

517

For citation: Chukhliaev P.V., Janibekov J.J., Khavkina D.A., Akhmedova M.D., Ruzhentsova T.A. EFFICACY AND SAFETY OF ANTIVIRAL THERAPY IN PATIENTS HOSPITALIZED WITH COVID-19 //New Day in Medicine 2(40)2022 512-517 https://clck.ru/eYqaq

LIST OF REFERENCES:

  1. Временные методические рекомендации Минздрава России «Профилактика, диагностика и лечение коронавирусной инфекции (COVID-19)», версия 15 (22.02.2022). Москва. 2022. 224 с.
  2. Alhazzani W., Møller M.H., Arabi Y.M., Loeb M., Gong M.N., Fan E., et al. Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19. Critical Care Medicine. 2020; 48(6):e440-e469. doi: 10.1097/CCM.0000000000004363.
  3. Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323:1061-1069.
  4. Arshad U., Pertinez H., Box H., Tatham L., Rajoki RKR, Curley P., et al. Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics. Clin Pharmacol Ther. 2020;108(4):775-790. doi: 10.1002/cpt.1909.
  5. Baden L.R., Rubin E.J. Covid-19 – The Search for Effective Therapy. N Engl J Med. 2020; 382(19):1851-1852. doi: 10.1056/NEJMe2005477.
  6. Barlow A., Landolf K.M., Barlow B., Yeung S.Ya., Heavner J.J., Claassen C.W., et al. Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019. Pharmacotherapy. 2020; 40(5):416-437. doi: 10.1002/phar.2398.
  7. Beigel J.H., Tomashek K.M., et al. ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 – Final Report. N Engl J Med. 2020;383(19):1813-1826. doi: 10.1056/NEJMoa2007764.
  8. Cai Q., Yang M., et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering (Beijing). 2020;6(10):1192-1198. doi: 10.1016/j.eng.2020.03.007.
  9. Руженцова Т.А., Чухляев П.В., Хавкина Д.А. и др. Необходимость и безопасность применения фавипиравира в лечении взрослых пациентов с нетяжелыми формами COVID. Эпидемиология и инфекционные болезни. Актуальные вопросы. 2020;10(4):38-44.
  10. Ruzhentsova T.A., Chukhliaev P.V., et al. Efficacy and safety of favipiravir in the complex therapy of mild and moderate COVID-19. Infectious diseases: news, opinions, training. 2020;4(9):8–19. doi: 10.33029/2305-3496-2020-9-00-0.
  11. Руженцова Т.А., Чухляев П.В., Хавкина Д.А. и др. Необходимость и безопасность Хавкина Д.А., Чухляев П.В., Руженцова Т.А., Гарбузов А.А. Неэффективность терапии COVID-19: причины и пути решения проблемы. Академия медицины и спорта. 2021;2(1):28-31.
  12. Agostini M.L., Andres E.L., Sims A.C., et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio 2018;9(2):e00221-18. doi: 10.1128/mBio.00221-18.
  13. Brown A.J., Won J.J., Graham R.L., et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral Res. 2019; 169:104541-104541. doi.org/10.1016/j.antiviral.2019.104541.
  14. Spinner C.D., Gottlieb R.L., Criner G.J., et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA 2020; 324:1048-1057.  doi:10.1001/jama.2020.16349.
  15. Grein J., Ohmagari N., Shin D., Diaz G., Asperges E., Castagna A, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020;382(24):2327-2336. doi: 10.1056/NEJMoa2007016.
  16. Martinez M.A. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother. 2020;64(5): e00399-20. doi: 10.1128/AAC.00399-20. 
  17. Wang Y., Zhang D., Du G., Du R., Zhao J., Yang J., et al. Remdesivir in adults with severe COVID-19: a randomised, double blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569-1578. doi.org/10.1016/S0140-6736(20)31022-9.
  18. Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;.323(13): 1239-1242. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32091533.

file

download